Cerus Corporation Company Profile (NASDAQ:CERS)

About Cerus Corporation (NASDAQ:CERS)

Cerus Corporation logoCerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company's INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company's INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Devices & Implants
  • Sub-Industry: Health Care Supplies
  • Symbol: NASDAQ:CERS
  • CUSIP: 15708510
  • Web: www.cerus.com
Capitalization:
  • Market Cap: $275.03 million
  • Outstanding Shares: 109,137,000
Average Prices:
  • 50 Day Moving Avg: $2.51
  • 200 Day Moving Avg: $3.04
  • 52 Week Range: $1.93 - $6.59
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.94
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $36.83 million
  • Price / Sales: 7.47
  • Book Value: $0.36 per share
  • Price / Book: 7.00
Profitability:
  • EBIDTA: ($61,750,000.00)
  • Net Margins: -164.39%
  • Return on Equity: -120.31%
  • Return on Assets: -65.38%
Debt:
  • Debt-to-Equity Ratio: 0.30%
  • Current Ratio: 2.94%
  • Quick Ratio: 2.46%
Misc:
  • Average Volume: 861,062 shs.
  • Beta: 1.79
  • Short Ratio: 14.04
 

Frequently Asked Questions for Cerus Corporation (NASDAQ:CERS)

What is Cerus Corporation's stock symbol?

Cerus Corporation trades on the NASDAQ under the ticker symbol "CERS."

How were Cerus Corporation's earnings last quarter?

Cerus Corporation (NASDAQ:CERS) announced its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.16) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.16). The business had revenue of $9.53 million for the quarter, compared to analyst estimates of $9.14 million. Cerus Corporation had a negative net margin of 164.39% and a negative return on equity of 120.31%. The company's revenue was up 3.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.18) EPS. View Cerus Corporation's Earnings History.

When will Cerus Corporation make its next earnings announcement?

Cerus Corporation is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Cerus Corporation.

Where is Cerus Corporation's stock going? Where will Cerus Corporation's stock price be in 2017?

4 brokerages have issued 1 year price objectives for Cerus Corporation's stock. Their predictions range from $5.00 to $10.00. On average, they anticipate Cerus Corporation's stock price to reach $7.25 in the next year. View Analyst Ratings for Cerus Corporation.

What are analysts saying about Cerus Corporation stock?

Here are some recent quotes from research analysts about Cerus Corporation stock:

  • 1. According to Zacks Investment Research, "Cerus Corporation is developing medical products based on a platform technology that prevents nucleic acid replication. The company's initial application of this technology is the development of systems to inactivate viruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation. " (6/27/2017)
  • 2. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating and $9 PT following mixed 4Q16 results and strong 2017 guidance. The company reports that 55 U.S. hospitals have begun receiving INTERCEPT platelets, with a pipeline of ~10 more expected in 1Q17 and additional hospitals expected in 2Q17. Driving that adoption is the key to 2017, in our view, and the company is sharply focused on driving hospital adoption through expanded medical science liaisons and hospital implementation teams. That said, some hospitals are already ordering as many units as are available and others are not yet in use due to capacity constraints, which we expect to be alleviated as more of the 36 installed systems come online. We continue to believe 2017 may be a breakout year as U.S. INTERCEPT utilization drives kit sales and the company progresses with both its U.S. and European red blood cell programs." (3/8/2017)

Who are some of Cerus Corporation's key competitors?

Who are Cerus Corporation's key executives?

Cerus Corporation's management team includes the folowing people:

  • Daniel N. Swisher Jr., Independent Chairman of the Board
  • William M. Greenman, President, Chief Executive Officer, Director
  • Kevin D. Green, Chief Financial Officer, Vice President - Finance
  • Caspar Hogeboom, President, Cerus Europe and EEMEA
  • Laurence M. Corash M.D., Senior Vice President, Chief Medical and Chief Scientific Officer, Director
  • Carol M. Moore, Senior Vice President - Regulatory Affairs, Quality and Clinical
  • Richard J. Benjamin, Chief Medical Officer
  • Vivek K. Jayaraman, Chief Commercial Officer
  • Chrystal N. Menard, Chief Legal Officer and General Counsel
  • Timothy Bruce Anderson, Independent Director

Who owns Cerus Corporation stock?

Cerus Corporation's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Elk Creek Partners LLC (5.52%), Vanguard Group Inc. (4.71%), Peregrine Capital Management LLC (3.17%), Senvest Management LLC (2.83%), State Street Corp (1.67%) and ARK Investment Management LLC (1.62%). Company insiders that own Cerus Corporation stock include Carol Moore, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin and William Mariner Greenman. View Institutional Ownership Trends for Cerus Corporation.

Who sold Cerus Corporation stock? Who is selling Cerus Corporation stock?

Cerus Corporation's stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Wells Fargo & Company MN, Peregrine Capital Management LLC, Stoneridge Investment Partners LLC, New York State Common Retirement Fund, TIAA CREF Investment Management LLC, Schwab Charles Investment Management Inc. and Bank of New York Mellon Corp. Company insiders that have sold Cerus Corporation stock in the last year include Carol Moore, Kevin Dennis Green, Richard J Benjamin and William Mariner Greenman. View Insider Buying and Selling for Cerus Corporation.

Who bought Cerus Corporation stock? Who is buying Cerus Corporation stock?

Cerus Corporation's stock was acquired by a variety of institutional investors in the last quarter, including Elk Creek Partners LLC, ARK Investment Management LLC, Delta Lloyd Asset Management N.V., Vanguard Group Inc., Marshall Wace North America L.P., Bamco Inc. NY, First Midwest Bank Trust Division and Salzhauer Michael. View Insider Buying and Selling for Cerus Corporation.

How do I buy Cerus Corporation stock?

Shares of Cerus Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cerus Corporation's stock price today?

One share of Cerus Corporation stock can currently be purchased for approximately $2.52.


MarketBeat Community Rating for Cerus Corporation (NASDAQ CERS)
Community Ranking:  3.9 out of 5 (star star star)
Outperform Votes:  265 (Vote Outperform)
Underperform Votes:  73 (Vote Underperform)
Total Votes:  338
MarketBeat's community ratings are surveys of what our community members think about Cerus Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cerus Corporation (NASDAQ:CERS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $7.25 (187.70% upside)

Analysts' Ratings History for Cerus Corporation (NASDAQ:CERS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/7/2017Cantor FitzgeraldReiterated RatingBuy$7.00HighView Rating Details
5/28/2017BTIG ResearchReiterated RatingBuy$5.00LowView Rating Details
4/17/2017Cowen and CompanyLower Price TargetOutperform$9.50 -> $7.00LowView Rating Details
3/8/2017FBR & CoSet Price TargetBuy$10.00LowView Rating Details
8/6/2016Robert W. BairdSet Price TargetBuy$9.00 -> $10.00N/AView Rating Details
2/6/2016StephensReiterated RatingBuyN/AView Rating Details
12/17/2015WedbushDowngradeOutperform -> Neutral$6.50N/AView Rating Details
(Data available from 9/21/2015 forward)

Earnings

Earnings History for Cerus Corporation (NASDAQ:CERS)
Earnings by Quarter for Cerus Corporation (NASDAQ:CERS)
Earnings History by Quarter for Cerus Corporation (NASDAQ CERS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017        
8/3/2017Q2 2017($0.16)($0.16)$9.14 million$9.53 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.17)($0.18)$8.98 million$7.01 millionViewListenView Earnings Details
3/7/2017Q4 2016($0.16)($0.13)$11.29 million$10.10 millionViewListenView Earnings Details
11/3/2016Q316($0.17)($0.14)$10.34 million$10.20 millionViewN/AView Earnings Details
8/4/2016Q216($0.17)($0.18)$8.88 million$9.25 millionViewN/AView Earnings Details
5/3/2016Q1($0.16)($0.17)$8.29 million$7.60 millionViewN/AView Earnings Details
3/8/2016Q415($0.16)($0.15)$9.72 million$9.70 millionViewListenView Earnings Details
11/5/2015Q315($0.16)($0.17)$10.00 million$8.04 millionViewN/AView Earnings Details
8/6/2015Q215($0.15)($0.17)$8.71 million$8.83 millionViewN/AView Earnings Details
5/5/2015Q214($0.16)($0.21)$7.70 million$7.70 millionViewN/AView Earnings Details
2/26/2015Q114($0.15)($0.25)$10.36 million$9.70 millionViewN/AView Earnings Details
11/4/2014Q413($0.13)($0.15)$9.83 million$10.36 millionViewN/AView Earnings Details
7/31/2014Q313($0.13)($0.16)$8.17 million$8.60 millionViewN/AView Earnings Details
5/1/2014Q313($0.09)($0.04)$9.65 million$7.86 millionViewN/AView Earnings Details
2/25/2014Q213($0.09)($0.10)$11.77 million$9.23 millionViewN/AView Earnings Details
10/29/2013($0.09)($0.29)$10.34 million$10.54 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cerus Corporation (NASDAQ:CERS)
2017 EPS Consensus Estimate: ($0.55)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.15)($0.15)($0.15)
Q2 20171($0.14)($0.14)($0.14)
Q3 20171($0.13)($0.13)($0.13)
Q4 20171($0.13)($0.13)($0.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cerus Corporation (NASDAQ:CERS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Cerus Corporation (NASDAQ:CERS)
Insider Ownership Percentage: 7.40%
Institutional Ownership Percentage: 58.26%
Insider Trades by Quarter for Cerus Corporation (NASDAQ:CERS)
Institutional Ownership by Quarter for Cerus Corporation (NASDAQ:CERS)
Insider Trades by Quarter for Cerus Corporation (NASDAQ:CERS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/11/2017Laurence M CorashInsiderBuy92,796$2.45$227,350.20View SEC Filing  
3/15/2017Kevin Dennis GreenCFOSell2,343$4.21$9,864.03View SEC Filing  
3/15/2017William Mariner GreenmanInsiderSell8,786$4.21$36,989.06View SEC Filing  
3/14/2017Carol MooreSVPSell2,377$4.15$9,864.55View SEC Filing  
3/14/2017Richard J BenjaminInsiderSell1,189$4.15$4,934.35View SEC Filing  
8/22/2016Kevin Dennis GreenCFOSell17,150$6.80$116,620.00View SEC Filing  
8/19/2015Laurence M CorashInsiderBuy25,900$4.99$129,241.00View SEC Filing  
8/18/2015Laurence M CorashInsiderBuy84,600$4.77$403,542.00View SEC Filing  
11/10/2014William Mariner GreenmanCEOBuy21,800$3.93$85,674.00View SEC Filing  
11/19/2012William Mariner GreenmanCEOBuy3,200$3.02$9,664.00View SEC Filing  
11/16/2012Laurence M CorashInsiderBuy2,000$2.85$5,700.00View SEC Filing  
11/16/2012William Mariner GreenmanCEOBuy13,800$2.85$39,330.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Cerus Corporation (NASDAQ:CERS)
Latest Headlines for Cerus Corporation (NASDAQ:CERS)
Source:
DateHeadline
finance.yahoo.com logoCerus to Present at Cantor Fitzgerald’s Annual Healthcare Conference on September 27, 2017
finance.yahoo.com - September 20 at 5:52 PM
americanbankingnews.com logoComparing Stryker Corporation (SYK) & Cerus Corporation (CERS)
www.americanbankingnews.com - September 17 at 2:50 AM
americanbankingnews.com logoCerus Corporation (CERS) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - September 16 at 1:02 PM
seekingalpha.com logoCerus Corporation (CERS) Presents At 24th Annual NewsMakers in the Biotech Industry - Slideshow
seekingalpha.com - September 11 at 5:43 PM
americanbankingnews.com logoFinancial Contrast: Glaukos Corporation (GKOS) versus Cerus Corporation (CERS)
www.americanbankingnews.com - September 9 at 2:12 AM
americanbankingnews.com logoCerus Corporation (CERS) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - September 3 at 7:08 PM
americanbankingnews.com logoHead-To-Head Review: Stryker Corporation (SYK) and Cerus Corporation (CERS)
www.americanbankingnews.com - September 1 at 9:10 AM
americanbankingnews.com logoTrivascular Technologies (TRIV) versus Cerus Corporation (CERS) Head-To-Head Analysis
www.americanbankingnews.com - August 31 at 8:08 AM
finance.yahoo.com logoCerus to Present at Two Upcoming Conferences
finance.yahoo.com - August 30 at 4:47 PM
americanbankingnews.com logoCerus Corporation (CERS) Downgraded by BidaskClub
www.americanbankingnews.com - August 25 at 11:02 PM
seekingalpha.com logoIs Cerus's Intercept A Pick-6?
seekingalpha.com - August 22 at 5:39 PM
americanbankingnews.com logoCerus Corporation (CERS) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - August 22 at 12:50 PM
americanbankingnews.com logoCerus Corporation (NASDAQ:CERS) Insider Laurence M. Corash Acquires 92,796 Shares
www.americanbankingnews.com - August 14 at 11:12 PM
americanbankingnews.com logoCritical Analysis: HeartWare International (HTWR) and Cerus Corporation (CERS)
www.americanbankingnews.com - August 12 at 12:30 AM
seekingalpha.com logoCerus' (CERS) CEO Obi Greenman on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 6 at 9:26 PM
finance.yahoo.com logoEdited Transcript of CERS earnings conference call or presentation 3-Aug-17 8:15pm GMT
finance.yahoo.com - August 4 at 4:40 AM
finance.yahoo.com logoCerus reports 2Q loss
finance.yahoo.com - August 3 at 11:37 PM
americanbankingnews.com logoCerus Corporation (NASDAQ:CERS) Issues Quarterly Earnings Results
www.americanbankingnews.com - August 3 at 8:09 PM
finance.yahoo.com logoCerus Corporation Reports Second Quarter 2017 Results
finance.yahoo.com - August 3 at 6:34 PM
finance.yahoo.com logoCerus Enters Into $40 Million Amended Growth Capital Agreement
finance.yahoo.com - August 2 at 5:51 PM
businesswire.com logoCerus Announces Expanded Supply Agreement with French ... - Business Wire (press release)
www.businesswire.com - August 1 at 10:48 PM
finance.yahoo.com logoCerus Announces Expanded Supply Agreement with French National Blood Service
finance.yahoo.com - August 1 at 5:48 PM
streetinsider.com logoCerus (CERS) Announces Collaboration with Central California Blood Center to Manufacture Cryoprecipitate
www.streetinsider.com - July 29 at 4:47 AM
nasdaq.com logoBUZZ-US STOCKS ON THE MOVE- Twitter, New York Times, F5 Networks - Nasdaq
www.nasdaq.com - July 27 at 4:31 PM
streetinsider.com logoCerus (CERS) Announces Collaboration with Central California ... - StreetInsider.com
www.streetinsider.com - July 27 at 4:31 PM
finance.yahoo.com logoCerus Announces Collaboration with Central California Blood Center to Manufacture Pathogen-Reduced Cryoprecipitate
finance.yahoo.com - July 27 at 4:31 PM
americanbankingnews.com logoCerus Corporation (CERS) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - July 27 at 10:00 AM
finance.yahoo.com logoCerus to Release Second Quarter 2017 Results on August 3, 2017
finance.yahoo.com - July 21 at 3:21 PM
americanbankingnews.com logoEndologix (ELGX) vs. Cerus Corporation (CERS) Head to Head Analysis
www.americanbankingnews.com - July 19 at 8:25 AM
finance.yahoo.com logoETFs with exposure to Cerus Corp. : July 11, 2017
finance.yahoo.com - July 11 at 6:10 PM
americanbankingnews.com logoCerus Corporation (NASDAQ:CERS) Expected to Announce Earnings of -$0.15 Per Share
www.americanbankingnews.com - July 4 at 7:30 AM
americanbankingnews.com logoCerus Corporation (NASDAQ:CERS) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 3 at 12:40 PM
americanbankingnews.com logoCerus Corporation (CERS) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - June 27 at 8:58 PM
streetinsider.com logoCerus (CERS) Says INTERCEPT Blood System Highlighted at ISBT - StreetInsider.com
www.streetinsider.com - June 21 at 5:21 PM
finance.yahoo.com logoINTERCEPT Blood System Highlighted at the International Society of Blood Transfusion (ISBT)
finance.yahoo.com - June 21 at 5:21 PM
americanbankingnews.com logoValuEngine Lowers Cerus Corporation (CERS) to Strong Sell
www.americanbankingnews.com - June 17 at 8:28 PM
americanbankingnews.com logo$10.46 Million in Sales Expected for Cerus Co. (CERS) This Quarter
www.americanbankingnews.com - June 10 at 10:30 AM
americanbankingnews.com logoZacks: Analysts Expect Cerus Co. (CERS) Will Announce Earnings of -$0.15 Per Share
www.americanbankingnews.com - June 8 at 7:46 AM
fool.com logoHere's Why Cerus Corporation Rose as Much as 17.4% Today
www.fool.com - June 7 at 6:36 PM
seekingalpha.com logoPAS shortage less disruptive than expected, Cerus up 13%
seekingalpha.com - June 7 at 6:36 PM
finance.yahoo.com logoCerus Provides Update on U.S. Platelet Additive Solution (PAS) Supply
finance.yahoo.com - June 7 at 1:33 PM
finance.yahoo.com logoHere's Why Cerus Corporation Rose as Much as 17.4% Today
finance.yahoo.com - June 7 at 1:33 PM
americanbankingnews.com logoCerus Co. (CERS) Earns "Buy" Rating from Cantor Fitzgerald
www.americanbankingnews.com - June 7 at 11:38 AM
americanbankingnews.com logoCerus Co. (CERS) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - June 6 at 10:18 AM
americanbankingnews.com logoCerus Co. (CERS) Earns "Buy" Rating from BTIG Research
www.americanbankingnews.com - May 28 at 7:20 AM
finance.yahoo.com logoHere's Why Cerus Corporation Rose as Much as 16.3% Today
finance.yahoo.com - May 26 at 9:47 PM
americanbankingnews.com logoCerus Co. (CERS) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - May 26 at 8:42 PM
fool.com logoHere's Why Cerus Corporation Rose as Much as 16.3% Today
www.fool.com - May 26 at 5:02 PM
thestreet.com logoBiotech Movers: Cerus, Alexion, NantKwest - TheStreet.com
www.thestreet.com - May 25 at 12:19 AM
americanbankingnews.com logoCerus Co. (CERS) PT Set at $7.00 by Cantor Fitzgerald
www.americanbankingnews.com - May 23 at 10:37 PM

Social

Chart

Cerus Corporation (CERS) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by MarketBeat.com Staff